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Abstract
Rationale—The lack of consistent associations between clinical outcomes and microbiological 
responses to therapy for some infectious diseases has raised questions about the adequacy of 
microbiological endpoints for tuberculosis treatment trials.
Objectives—To evaluate the association between symptoms and microbiological response to 
tuberculosis treatment.
Methods—We performed a retrospective analysis of four clinical trials in which participants had 
culture-positive tuberculosis, standardized symptom assessment, and follow-up mycobacterial 
cultures. Two trials (studies 22 and 23) followed participants to identify recurrent tuberculosis; 
participants in studies 27 and 28 were only followed to treatment completion.
Measurements and Main Results—This analysis included 1,978 participants; 39 (2.0%) had 
culture-confirmed treatment failure, and 75 (3.9%) had culture-confirmed recurrence. Productive 
cough was associated with indices of increased mycobacterial burden at diagnosis (acid-fast smear 
grade, severity of radiographic abnormalities). Fever and sweats improved rapidly with treatment, 
whereas productive cough decreased more slowly and was present in 20% of visits after treatment 
completion. During treatment, study participants with productive cough more often had concurrent 
culture positivity compared with those without productive cough (studies 22 and 23: adjusted odds 
ratio, 1.80; 95% confidence interval [CI], 1.33–2.44). Finally, symptoms during the latter part of 
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treatment and follow-up were associated with culture-confirmed treatment failure and recurrence 
in studies 22 and 23 (for cough: adjusted hazard ratio, 2.07; 95% CI, 1.23–3.49; for fever: adjusted 
hazard ratio, 5.05; 95% CI, 2.76–9.19).
Conclusions—There are consistent relationships between symptoms and microbiological 
indices of tuberculosis, including measures of mycobacterial burden at baseline, culture positivity 
during treatment, and time to culture-confirmed treatment failure and recurrence.
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The field of tuberculosis (TB) treatment has emphasized bacteriological outcomes of therapy 
for several decades (1). The traditional endpoints for clinical trials of TB treatment have 
been treatment failure (sputum culture-positivity at or near the end of treatment) and 
recurrent disease (culture positivity after the completion of treatment). However, a recent 
review of the literature by the Food and Drug Administration revealed a lack of recent 
attention to the association between these microbiologically defined outcomes of TB 
treatment and the symptoms of TB (2). The lack of consistent associations between clinical 
and microbiologically defined responses to therapy in other infectious diseases (e.g., otitis 
media, bacterial pneumonia [3, 4]) raises questions about the adequacy of microbiological 
endpoints for TB treatment trials.
Previous studies have established that quality of life is decreased in patients with TB and 
improves with treatment (5–8). Residual symptoms and pulmonary impairment have been 
reported among patients with microbiologically cured pulmonary TB (9, 10), presumably 
reflecting damage to the lungs that occurred before control of the infection or because of 
concomitant lung disease. Results from these studies are limited because they did not 
include an assessment of participants in clinical trials and did not compare symptoms with 
microbiological response to treatment. We used results from four clinical trials performed by 
the Tuberculosis Trials Consortium (TBTC) to evaluate the association between symptoms 
and concurrent microbiological status before, during, and after treatment.
Materials and Methods
The TBTC has used a standard set of questions to assess the presence of common symptoms 
of TB: fever; sweats (soaking clothes or sheets); cough; and, if present, whether the cough is 
productive. Symptoms and body weight were assessed at enrollment, every 2 to 4 weeks 
during treatment, every 3 to 6 months during follow-up to detect recurrent TB, and at the 
time of suspected treatment failure or recurrence. The severity of these symptoms was not 
uniformly assessed in these studies. Detailed information on the demographic and clinical 
characteristics of the patients included and for definitions used throughout the analysis is 
provided in the online supplement.
The four clinical trials used for this analysis were limited to patients with culture-positive 
TB who were treated using directly observed therapy (Table 1) (11–15). Two trials (studies 
22 and 23, conducted in the United States and Canada) were chosen because they included 
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follow-up after completion of therapy to detect recurrent TB. Furthermore, study 23 
evaluated TB treatment for patients with HIV coinfection. Studies 27 and 28 (conducted in 
the United States, Uganda, South Africa, Brazil, and Spain) were included because they 
included frequent study visits during the first 2 months of therapy and provided additional 
cases of treatment failure. However, patients were not followed beyond the end of treatment; 
hence, these trials cannot be used for analyses of the relationship between symptoms and 
recurrent TB.
Microbiological Techniques and Outcome Definitions
All four trials used both liquid and solid culture media results at each time point to 
determine microbiological outcomes. If either media type was positive for growth of 
Mycobacterium tuberculosis, the sputum culture was considered positive for that time point. 
“Treatment failure” was defined as a positive culture at or beyond 4 months of therapy but 
before its completion. “Recurrent tuberculosis” was defined as a positive culture after the 
completion of therapy and during 18 months of follow-up (Table 1). Paired baseline and 
failure/recurrence isolates underwent DNA fingerprinting. Though uncommon in these 
studies, three cases of apparent reinfection were included in this analysis (16).
Data Analysis
We used several methods to evaluate the association between symptoms and concurrent 
microbiological status before, during, and after treatment, including contingency tables, 
graphical summaries, regression with correlated data, and time to event.
We used contingency tables with Pearson’s chi-squared test to evaluate the association 
between symptoms at baseline and the following measures of the mycobacterial burden at 
baseline at or very near the initiation of treatment: sputum smear grade (high bacillary load 
was defined as ⩾ 1 acid-fast bacilli/field at 1,000×) and the severity of chest radiographic 
abnormalities.
We used graphical methods to depict the change in frequency of symptoms and culture 
positivity over the first 24 weeks after starting therapy. We evaluated the association between 
concurrent symptoms and positive sputum cultures during therapy using logistic regression 
analysis with generalized estimating equations to compensate for statistical dependence 
among multiple observations on individuals (17) (additional details are provided in the 
online supplement).
We used Cox proportional-hazard regression models to quantify the association of time to 
treatment failure or recurrence with concurrent symptoms. We assessed potential 
confounding by study and HIV status. Because the frequency of study visits differed, we 
performed all of these analyses separately for studies 22 and 23 and then for studies 27 and 
28. Statistical analyses were performed using SAS (version 9.2; SAS Institute, Inc., Cary, 
NC) and R (version 2.10.1; The R Foundation for Statistical Computing) (18).
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TBTC studies 22, 23, 27, and 28 collectively enrolled 2,025 patients (Table 2). Of these, 27 
patients had baseline cultures that were either negative or grew drug-resistant M. 
tuberculosis; these patients were discontinued from study therapy and not included in this 
analysis. The median age of the remaining cohort of 1,998 patients was 38.5 years 
(interquartile range 29, 49 yr), 73% were male, and 18% had HIV coinfection. Of the 1,998 
patients in the analysis, 39 had culture-confirmed treatment failure, and 75 had culture-
confirmed recurrence.
Association between Symptoms and Mycobacterial Burden at Baseline
Productive cough was more common among patients with high-grade sputum smear or 
pulmonary cavitation in studies 22, 27, and 28 (those studies with consistently collected 
baseline data) (Table 3). For example, in studies 27 and 28, 94% (450/480) of patients whose 
sputum had high-grade smear positivity had productive cough, compared with 86% 
(198/230) of patients whose sputum smear grade was less than 1 bacillus per high-power 
field (P < 0.001). The relationship between fever and sweats and measures of mycobacterial 
burden was less consistent, with a significant association in study 22 but not in studies 27 
and 28.
Change in Symptoms during Treatment
Fever and sweats improved rapidly with treatment (Figures 1A and 1B). By 6 to 8 weeks of 
treatment, fewer than 10% of patients had either of these symptoms. The prevalence of 
productive cough decreased steadily with treatment but was present in 35 to 50% of study 
patients at Week 8 of therapy (Figure 1C). Thereafter, the prevalence of productive cough 
remained at approximately 20% during or after therapy. For all three symptoms, the curves 
of the decrease in prevalence of symptoms were similar across studies. Sputum culture 
positivity declined steadily in the first 12 weeks of therapy, and very few patients had 
positive cultures at or after 16 weeks (Figure 1D).
Association between Symptoms and Mycobacterial Burden at Week 8 of Treatment
We initially focused on the 8-week time point, given the use of sputum culture status at that 
time point as a surrogate marker of the sterilizing effect of a therapeutic regimen (19). 
Productive cough at Week 8 was more common among patients with a positive sputum 
culture (Table 4). For example, in study 22, productive cough was present in 51% of those 
with a positive 8-week culture, compared with 29% of those with a negative culture (P < 
0.001). Furthermore, productive cough was consistently associated with high sputum smear 
grade. The association between productive cough and radiographic measures of disease 
severity was less consistent, being present in study 22 but not in studies 27 and 28. Fever and 
sweats were uncommon at Week 8 and showed no significant association with measures of 
mycobacterial burden (data not shown).
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Association between Symptoms and Concurrent Culture Positivity over the Course of 
Treatment
We used logistic regression analysis with generalized estimating equations to evaluate the 
association between productive cough and concurrent sputum culture positivity at any point 
during treatment. In an initial bivariate analysis adjusting for time on treatment, study 
participants with cough had twice the odds of having concurrent sputum culture positivity 
(studies 22 and 23: odds ratio [OR], 2.23; 95% confidence interval [CI], 1.70–2.92; studies 
27 and 28: OR, 2.27; 95% CI, (1.90–2.72) (Tables 5 and 6). These odds ratios were 
minimally attenuated (studies 22 and 23: adjusted OR, 1.80; 95% CI, 1.33–2.44 [P < 0.001]; 
studies 27 and 28: OR, 1.71; 95% CI, 1.41–2.07 [P < 0.001]) in multivariate models 
adjusting for factors that have previously been associated with treatment outcome (being 
underweight at diagnosis, weight change in the first 8 weeks of treatment, baseline bacillary 
load on sputum smear, bilateral and cavitary disease on chest radiography at baseline, HIV 
status, and enrollment at an African site [studies 27 and 28]).
Association between Symptoms and Culture-Confirmed Treatment Failure or Recurrence
Of the 89 patients who experienced culture-positive treatment failure or recurrence in studies 
22 and 23, 85 (96%) had concurrent information on symptoms. Of these 85 participants, 56 
(66%) had at least one symptom at the time of culture-confirmed treatment failure or 
recurrence. An additional 1,156 participants did not experience treatment failure or relapse 
and had symptom information at Week 16 or later. Fever (hazard ratio [HR], 5.68; 95% Wald 
CI, 3.15–10.24 [P < 0.001]) and productive cough (HR, 2.58; 95% CI, 1.58–4.22 [P = 
0.002]) were associated with culture-confirmed treatment failure or recurrent TB (Table 7). 
These associations attenuated only slightly when adjusted for other factors previously shown 
to be associated with treatment failure or recurrence in study 22 (11). In studies 27 and 28, 
25 participants experienced treatment failure, and an additional 666 participants with 
symptom information between Weeks 12 and 24 did not experience treatment failure. 
Productive cough was associated with culture-positive treatment failure (HR, 4.70; 95% CI, 
2.11–10.47 [P < 0.001]). None of the patients with treatment failure reported fever or sweats 
between Weeks 12 and 24. Because there were few visits at risk for treatment failure, we did 
not construct a multivariate hazard regression model for studies 27 and 28.
Discussion
Using data from four prospective clinical trials, we have shown consistent relationships 
between symptoms and microbiological outcomes of TB treatment. Symptoms were more 
common among patients with a greater burden of M. tuberculosis at the time of diagnosis. 
During treatment, the presence of concurrent productive cough was consistently associated 
with sputum culture positivity, including in models that adjusted for other factors that have 
been associated with disease severity. Finally, symptoms (productive cough and fever) were 
associated with the two microbiological outcomes that have been used in clinical trials over 
the past 40 years: culture-confirmed treatment failure and recurrence. Although there were 
minor differences in these associations in different clinical trials, the consistency in the 
response of symptoms to treatment and the consistency of the associations with culture 
positivity during treatment are impressive.
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Our results are similar to data from a clinical trial done in Uganda, Brazil, and the 
Philippines (20). In that study of 394 HIV-negative patients with culture-positive pulmonary 
TB, symptoms were associated with measures of mycobacterial burden at baseline, and 
symptoms improved quickly with therapy. Furthermore, symptoms (fever, cough, and chest 
pain) were more common at the time of recurrent culture positivity (microbiologic 
recurrence) than among patients who had negative cultures during follow-up.
The United States Food and Drug Administration is charged with assuring that new 
medications are both safe and effective. Demonstration of effectiveness requires 
improvement in how the patient feels, functions, or survives. The relationship between 
clinical symptoms and microbiological indices of TB had not been emphasized in clinical 
trials over the past 40 years, and the resultant lack of data has led to questions about the 
validity of sputum culture as an appropriate surrogate endpoint for licensure of new drugs.
Appropriate concerns have been raised about using microbiological culture as the primary 
outcome of treatment trials for infectious diseases such as otitis media; there is a weak 
relationship between conversion of cultures to negative and the clinical outcomes of such 
treatment (4). TB has several factors that make it quite different from bacterial pneumonia 
and similar acute bacterial infections. First, the pathogens that commonly cause acute 
bacterial infections (e.g., Streptococcus pneumoniae) can be commensal bacteria; therefore, 
culture positivity from cultures of nonsterile sites (e.g., sputum) at baseline or during 
treatment may represent colonization. In contrast, M. tuberculosis is not a commensal 
bacterium, so its presence in a culture is nearly always associated with disease (if laboratory 
cross-contamination has been ruled out). Furthermore, we have shown consistent 
relationships between symptoms of TB and a number of microbiological outcomes of 
therapy.
Despite the consistent relationship between productive cough and microbiological outcome 
of TB treatment, cough would be a problematic endpoint for TB treatment. Productive cough 
was present in approximately 20% of patients at any time point during the latter part of 
treatment and during follow-up after completion of therapy. It is likely that residual cough 
after microbiologically successful treatment represents residual pulmonary damage from 
TB, conditions associated with cough and risk for TB (e.g., tobacco use or silicosis), and/or 
other pulmonary diseases (e.g., asthma). However, the consistent relationship between 
productive cough and culture positivity demonstrates that it is appropriate to use 
microbiologically defined endpoints as the primary endpoints for TB treatment trials (21).
This study had at least four limitations. First, our analyses were limited to symptoms and 
other clinical features that were consistently measured across all four studies. Because the 
severity of symptoms was not uniformly recorded, we were not able to analyze the 
relationship between symptom severity and microbiological findings. Second, the four 
studies did not uniformly collect data on other potential causes of cough, such as tobacco 
use or history of specific pulmonary diseases, such as obstructive pulmonary disease or 
asthma. Third, mycobacterial culture techniques were not standardized other than requiring 
that specimens be cultured in a certified lab and include use of approved broth and solid 
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culture media. Finally, only two of the four studies included in this analysis followed 
patients for recurrent TB, limiting the power of this key association.
Conclusions
There are consistent relationships between symptoms and microbiological indices of TB, 
including measures of mycobacterial burden at baseline, culture positivity during treatment, 
and culture-confirmed treatment failure and recurrence. These consistent relationships 
demonstrate that the use of microbiological outcomes is appropriate in clinical trials of new 
agents for TB treatment.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Acknowledgments
The authors thank the many patients who contributed to the success of these trials, Dr. Kenneth Castro for continued 
support within the CDC, local TB program staff who assisted in the clinical management of the participants, and 
Awal Khan for assistance with legacy data.
Supported by the Division of Tuberculosis Elimination, Centers for Disease Control and Prevention, Atlanta, 
Georgia.
References
1. Fox W, Ellard GA, Mitchison DA. Studies on the treatment of tuberculosis undertaken by the British 
Medical Research Council tuberculosis units, 1946–1986, with relevant subsequent publications. Int 
J Tuberc Lung Dis. 1999; 3:S231–S279. [PubMed: 10529902] 
2. Food and Drug Administration. Issues in the design of clinical trials of antimycobacterial drugs for 
treatment of tuberculosis; public workshop [Internet]. 2009. [updated September 23, 2009: accessed 
January 25, 2011] Available from: http://www.fda.gov/Drugs/NewsEvents/ucm168975.htm
3. Wunderink RG. Surrogate markers and microbiologic end points. Clin Infect Dis. 2010; 51(Suppl 
1):S126–S130. [PubMed: 20597662] 
4. Johann-Liang R, Zalkikar J, Powers JH. Correlation between bacteriologic and clinical endpoints in 
trials of acute otitis media. Pediatr Infect Dis J. 2003; 22:936–937. author reply 937. [PubMed: 
14551499] 
5. Dhuria M, Sharma N, Narender Pal S, Ram Chander J, Saha R, Gopal Krishan I. A study of the 
impact of tuberculosis on the quality of life and the effect after treatment with dots. Asia Pac J 
Public Health. 2009; 21:312–320. [PubMed: 19443879] 
6. Marra CA, Marra F, Colley L, Moadebi S, Elwood RK, Fitzgerald JM. Health-related quality of life 
trajectories among adults with tuberculosis: differences between latent and active infection. Chest. 
2008; 133:396–403. [PubMed: 18198260] 
7. Guo N, Marra F, Marra CA. Measuring health-related quality of life in tuberculosis: a systematic 
review. Health Qual Life Outcomes. 2009; 7:14. [PubMed: 19224645] 
8. Chang B, Wu AW, Hansel NN, Diette GB. Quality of life in tuberculosis: a review of the English 
language literature. Qual Life Res. 2004; 13:1633–1642. [PubMed: 15651535] 
9. Miller TL, McNabb SJ, Hilsenrath P, Pasipanodya J, Weis SE. Personal and societal health quality 
lost to tuberculosis. PLoS ONE. 2009; 4:e5080. [PubMed: 19352424] 
10. Pasipanodya JG, Miller TL, Vecino M, Munguia G, Bae S, Drewyer G, Weis SE. Using the St. 
George respiratory questionnaire to ascertain health quality in persons with treated pulmonary 
tuberculosis. Chest. 2007; 132:1591–1598. [PubMed: 17890471] 
Hales et al. Page 7













11. Tuberculosis Trials Consortium. Once-weekly rifapentine and isoniazid versus twice-weekly 
rifampin and isoniazid in the continuation phase of therapy for drug-susceptible pulmonary 
tuberculosis: a prospective, randomized clinical trial among HIV-negative persons. Lancet. 2002; 
360:528–534. [PubMed: 12241657] 
12. Vernon A, Burman W, Benator D, Khan A, Bozeman L. Relapse with rifamycin monoresistant 
tuberculosis in HIV-infected patients treated with supervised once-weekly rifapentine and 
isoniazid. Lancet. 1999; 353:1843–1847. [PubMed: 10359410] 
13. Burman WJ, Goldberg S, Johnson JL, Muzanye G, Engle M, Mosher AW, Choudhri S, Daley CL, 
Munsiff SS, Zhao Z, et al. Moxifloxacin versus ethambutol in the first 2 months of treatment for 
pulmonary tuberculosis. Am J Respir Crit Care Med. 2006; 174:331–338. [PubMed: 16675781] 
14. Dorman SE, Johnson JL, Goldberg S, Muzanye G, Padayatchi N, Bozeman L, Heilig CM, 
Bernardo J, Choudhri S, Grosset JH, et al. Substitution of moxifloxacin for isoniazid during 
intensive phase treatment of pulmonary tuberculosis. Am J Respir Crit Care Med. 2009; 180:273–
280. [PubMed: 19406981] 
15. Burman W, Benator D, Vernon A, Khan A, Jones B, Silva C, Lahart C, Weis S, King B, Mangura 
B, et al. Acquired rifamycin resistance with twice-weekly treatment of HIV-related tuberculosis. 
Am J Respir Crit Care Med. 2006; 173:350–356. [PubMed: 16109981] 
16. Jasmer RM, Bozeman L, Schwartzman K, Cave MD, Saukkonen JJ, Metchock B, Khan A, Burman 
WJ. Recurrent tuberculosis in the united states and canada: Relapse or reinfection? Am J Respir 
Crit Care Med. 2004; 170:1360–1366. [PubMed: 15477492] 
17. Diggle, P., Liang, K-Y., Zeger, SL. Analysis of longitudinal data. New York: Clarendon Press; 
1994. 
18. R Development Core Team. R: A language and environment for statistical computing. 2.10.1. 
Vienna, Austria: R Foundation for Statistical Computing; 2009. 
19. Mitchison D. Assessment of new sterilizing drugs for treating pulmonary tuberculosis by culture at 
2 months. Am Rev Respir Dis. 1993; 147:1062–1063. [PubMed: 8466107] 
20. Bark CM, Dietze R, Okwera A, Quelapio MI, Thiel BA, Johnson JL. Clinical symptoms and 
microbiological outcomes in tuberculosis treatment trials. Tuberculosis (Edinb). 2011; 91:601–
604. [PubMed: 21813327] 
21. Hopewell P, Cynamon M, Starke J, Iseman M, O’Brien R. Evaluation of new anti-infective drugs 
for the treatment and prevention of tuberculosis. Infectious Diseases Society of America and the 
Food and Drug Administration. Clin Infect Dis. 1992; 15:S282–S295. [PubMed: 1477244] 
Hales et al. Page 8














Frequency of fever (A), sweats (B), productive cough (C), and culture positivity (by solid or 
liquid culture) (D) during Weeks 0 to 24 after initiation of tuberculosis treatment among 
patients in Tuberculosis Trials Consortium (TBTC) Studies 22, 23, 27, and 28. Study 23 data 
are not included for Week 0 because enrollment occurred after the beginning of treatment.
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Table 4
Associations between productive cough and culture results, sputum smear grade, and radiographic indices of 
disease severity at 8 weeks of therapy among patients in Tuberculosis Trials Consortium Studies 22, 23, 27, 
and 28
Study Laboratory and Radiographic Features of Tuberculosis Percent Reporting Productive Cough, n 
(%)
P Value*
22 and 23 (n = 1,246)† Sputum culture result
 Positive 103/208 (50)
 Negative 261/971 (27) <0.001
Smear grade
 Smear ⩾ 1 per high-power field 24/35 (69)
 Smear < 1 per high-power field 339/1,135 (30) <0.001
Chest radiographic features
 Cavitation 161/394 (41)
 No cavitation 186/766 (24) <0.001
Bilateral abnormalities 205/574 (36)
Unilateral abnormalities or normal 159/613 (26) <0.001
27 and 28 (n = 742)† Sputum culture result
 Positive 114/207 (55)
 Negative 144/417 (35) <0.001
Smear grade
 Smear ⩾ 1 per high-power field 36/44 (82)
 Smear < 1 per high-power field 219/571 (38) <0.001
Chest radiographic features
 Cavitation 203/506 (40)
 No cavitation 69/175 (39) 0.89
Bilateral abnormalities 170/386 (44)
Unilateral abnormalities or normal 102/295 (35) 0.01
*
P value for Pearson’s chi-squared test.
†
Missing values for symptoms, smear grade, or chest radiographic features may reduce denominator totals.
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Table 5
Partially and fully adjusted models of the association between the presence of symptoms and concurrent 
culture positivity during tuberculosis therapy in Tuberculosis Trials Consortium studies 22 and 23
Term Partially Adjusted Model Fully Adjusted Model
OR (95% CI) P Value OR (95% CI) P Value
Symptoms
 Productive cough 2.23 (1.70–2.92) <0.001 1.80 (1.33–2.44) <0.001
 Fever 1.24 (0.74–2.07)  0.42 1.42 (0.77–2.63)  0.26
 Sweats 0.64 (0.38–1.05)    0.078 0.70 (0.40–1.22)  0.21
Time on therapy*
 Weeks 8–16 0.65 (0.61–0.69) <0.001 0.63 (0.59–0.68) <0.001
 Weeks 16–24 0.88 (0.77–1.01)    0.074 0.90 (0.78–1.04)  0.14
Weight†
 Underweight at diagnosis 1.54 (1.10–2.15)    0.011
 Gained > 4 kg 1.14 (0.78–1.67)  0.50
 Any weight loss 0.93 (0.56–1.54)  0.77
 Missing weight change 1.79 (1.01–3.14)    0.045
Severity of disease at baseline
 Smear ⩾ 1 AFB/field at 1,000× 2.31 (1.64–3.24) <0.001
 Cavitary disease 2.75 (1.91–3.98) <0.001
 Bilateral disease 1.78 (1.25–2.53)    0.001
Other
 HIV positive 0.33 (0.16–0.66)    0.002
Definition of abbreviations: AFB = acid-fast bacilli; CI = confidence interval; OR = odds ratio.
*
Time on therapy was modeled as two separate continuous variables, each with different slopes. The odds ratio represents weekly change in odds 
during the indicated time period since start of therapy.
†
Weight change over Weeks 0 to 8, with a gain 0–4 kg as referent.
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Table 6
Partially and fully adjusted models of the association between the presence of symptoms and concurrent 
culture positivity during tuberculosis therapy in Tuberculosis Trials Consortium studies 27 and 28
Term Partially Adjusted Model Fully Adjusted Model
OR (95% CI) P Value OR (95% CI) P Value
Symptoms
 Productive cough 2.27 (1.90–2.72) <0.001 1.71 (1.41–2.08) <0.001
 Fever 1.26 (0.83–1.91)  0.28 1.25 (0.80–1.94)  0.33
 Sweats 0.95 (0.66–1.38)  0.81 0.96 (0.63–1.46)  0.84
Time on therapy*
 Weeks 2–8 0.66 (0.63–0.68) <0.001 0.60 (0.57–0.63) <0.001
 Weeks 8–16 0.75 (0.71–0.79) <0.001 0.73 (0.70–0.77) <0.001
 Weeks 16–24 0.90 (0.82–1.00)    0.042 0.90 (0.82–0.99)    0.024
Weight†
 Underweight at diagnosis 1.22 (0.96–1.57)  0.11
 Gained > 4 kg 0.88 (0.59–1.31)  0.53
 Any weight loss 0.93 (0.58–1.48)  0.75
 Missing weight change 0.81 (0.62–1.07)  0.14
Severity of disease at baseline
 Smear ⩾ 1 AFB/field at 1,000× 1.93 (1.49–2.51) <0.001
 Cavitary disease 1.85 (1.41–2.43) <0.001
 Bilateral disease 1.59 (1.25–2.03) <0.001
Other
 African site 2.73 (2.05–3.64) <0.001
 HIV positive 0.67 (0.47–0.97)    0.032
Definition of abbreviations: AFB = acid-fast bacilli; CI = confidence interval; OR = odds ratio.
*
Time on therapy was modeled as three separate continuous variables, each with different slopes. The odds ratio represents weekly change in odds 
during the indicated time period since start of therapy.
†
Weight change over Weeks 0 to 8, with a gain of 0–4 kg as referent.
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Table 7
Hazard regression analysis from Cox regression analysis of the association between the presence of symptoms 
and time to treatment failure or recurrence after week 12 in Studies 22 and 23
Term Partially Adjusted Model Fully Adjusted Model
HR (95% CI) P Value HR (95% CI) P Value
Symptoms
 Productive cough 2.58 (1.58–4.22) <0.001 2.07 (1.23–3.49)    0.006
 Fever 5.68 (3.15–10.24) <0.001 5.04 (2.76–9.19) <0.001
 Sweats 1.61 (0.88–2.96)  0.12 2.26 (1.22–4.16)    0.009
Weight*
 Underweight at diagnosis 1.64 (1.03–2.59)    0.036
 Gained > 4 kg 1.05 (0.64–1.71)  0.85
 Any weight loss 0.60 (0.28–1.29)  0.19
 Missing weight change 0.62 (0.24–1.60)  0.33
Severity of disease at baseline
 Smear ⩾ 1 AFB/field at 1,000× 1.22 (0.77–1.93)  0.39
 Cavitary disease 3.34 (1.91–5.84) <0.001
 Bilateral disease 2.11 (1.25–3.56)    0.005
Other
 HIV positive 1.12 (0.58–2.17)  0.73
Definition of abbreviations: AFB = acid-fast bacilli; CI = confidence interval; OR = odds ratio.
*
Weight change over Weeks 0 to 8, with a gain 0 to 4 kg as referent.
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